The Final Frontier: Emerging Strategies in HER2-Positive Breast Cancer Brain Metastases

Program Description

Breast cancer (BC) is the second most common cause of brain metastases (BM) with the highest risk (up to 50%) in patients with human epidermal growth factor receptor 2 (HER2)-positive disease. For patients with BCBM, prognosis is poor and long-term survival is rare. Recently, clinical trials of targeted systemic therapies have finally begun to include patients with HER2-positive BCBM; however, with data continuously evolving, the translation into clinical strategy may remain unclear.

For this program, 32 renowned BC specialists from the United States (US) and European Union (EU) completed a questionnaire documenting their perspectives on several of the most deeply debated and evolving issues in the field including optimal screening practices, monitoring techniques, and therapeutic approaches. Watch Drs Komal Jhaveri, Javier Cortes, and Sara Hurvitz discuss the results in the context of their own experience and modern data, providing insight into evolving best practices. See how your approaches compare via intra-activity polling and gather clinical pearls to help optimize clinical decisions and improve patient outcomes.

Target Audience

The target audience for this CME initiative includes medical, radiation, and neuro-oncologists, and advanced practice professionals (APPs) working in oncology care settings.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

  • Describe the incidence and unique disease pathogenesis of HER2-positive BCBM to raise awareness among the medical community to ensure prompt screening and timely access to treatment
  • Appraise available and emerging data on the use of local and systemic treatment approaches for HER2-positive BCBM to improve evidence-based decision making, treatment sequencing, and patient outcomes
  • Identify emerging research data with novel systemic therapies for patients with HER2-positive BCBM to educate clinicians on the expansion of therapeutic options
Course summary
Available credit: 
  • 0.75 AAPA Category I CME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance
Course opens: 
12/30/2024
Course expires: 
12/30/2025
Cost:
$0.00
Rating: 
0
   Komal Jhaveri, MD, FACP (Moderator)
   Patricia and James Cayne Chair for Junior Faculty
   Associate Attending
   Breast Medicine Service and Early Drug Development Service
   Section Head, Endocrine Therapy Research Program
   Clinical Director, Early Drug Development Service
   Department of Medicine
   Memorial Sloan Kettering Cancer Center/Evelyn H. Lauder Breast and Imaging Center
                                Associate Professor of Medicine
                                Weill Cornell Medical College
                                New York, NY
   Javier Cortes, MD, PhD
   Head of International Breast Cancer Center (IBCC)
   Barcelona, Spain & IOB Madrid, Spain
 
 
 
 
 
 
   Sara A Hurvitz, MD, FACP
   Professor of Medicine
   Head, Division of Hematology and Oncology
   Department of Medicine, UW Medicine
   Senior Vice President, Clinical Research Division
   Fred Hutchinson Cancer Center
                                Seattle, WA

This activity is jointly provided by Partners for Advancing Clinical Education (PACE) and Efficient LLC.

          image   

Joint Accreditation Statement

image

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (PACE) and Efficient LLC. PACE is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation Statement

PHYSICIAN CREDIT
PACE designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
 
PA CONTINUING MEDICAL EDUCATION
PACE has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credits. Approval is valid until December 20, 2025. PAs should only claim credit commensurate with the extent of their participation.
 
CERTIFICATE OF PARTICIPATION FOR OTHER HEALTHCARE PROFESSIONALS
A Certificate of Participation will be given upon completion of the enduring activity enabling participants to register their credit with the appropriate licensing boards or associations.

Faculty and Disclosure of Conflicts of Interest

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Jhaveri reported the following relationships:
  • Consulting Fees: AbbVie Inc.; AstraZeneca; Blueprint Medicines Corporation; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Jounce Therapeutics, Inc.; Loxo Oncology; The Menarini Group; Novartis Pharmaceuticals Corporation; Olema Oncology; Pfizer; Scorpion Therapeutics; Seagen Inc.; Stemline Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd.; and Taiho Oncology, Inc.
  • Grants/Research Support: AstraZeneca; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Loxo Oncology; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.
Dr. Cortez reported the following financial relationships:
  • Consulting Fees: AbbVie Inc.; AstraZeneca; Bioasis Technologies, Inc.; Biocon; BioInvent International AB; BioNTech SE; Boehringer Ingelheim Pharmaceuticals, Inc.; BridgeBio; Clovis Oncology; Daiichi Sankyo Co., Ltd; Ellipses Pharma; ExpreS2ion Biotechnologies ApS; F. Hoffmann-La Roche Ltd; GEMoaB GmbH; Gilead Sciences, Inc.; HiberCell; Jazz Pharmaceuticals, Inc.; Leuko Labs Inc.; Lilly; The Menarini Group; Merck Sharp & Dohme LLC; Reveal Genomics, S.L.; Scorpion Therapeutics, Inc.; Seattle Genetics; and Zymeworks BC Inc.
  • Grants/Research Support: ARIAD Pharmaceuticals, Inc.; AstraZeneca; Baxalta GmbH/LES LABORATOIRES SERVIER; Bayer Corporation; Eisai Inc.; F. Hoffmann-La Roche Ltd; Guardant Health; IQVIA Inc.; Merck Sharp & Dohme LLC; Pfizer; PIQUR Therapeutics; and Queen Mary University of London. All to institution.
Dr Hurvitz reported the following financial relationships:
  • Grants/Research Support: Ambrx, Amgen Inc, Arvinas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Celcuity, CytomX Therapeutics, Daiichi Sankyo Inc, Dantari, Dignitana AB, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, Greenwich LifeSciences Inc, GSK, Lilly, MacroGenics Inc, Novartis, OBI Pharma Inc, Orinove Inc, Orum Therapeutics, Pfizer Inc, Phoenix Molecular Designs, Pieris Pharmaceuticals Inc, Puma Biotechnology Inc, Radius Health Inc, Samumed, Sanofi, Seagen Inc, Stemline Therapeutics Inc, Zymeworks Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Commercial Support

This activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.

Available Credit

  • 0.75 AAPA Category I CME
  • 0.75 AMA PRA Category 1 Credit™
  • 0.75 Attendance

Price

Cost:
$0.00
Please login or register to take this course.